HR+/HER2- metastatic breast cancer
Clinical trials for HR+/HER2- metastatic breast cancer explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- metastatic breast cancer trials appear
Sign up with your email to follow new studies for HR+/HER2- metastatic breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo for advanced breast cancer shows promise but trial halted early
Disease control Stopped earlyThis phase 2 study tested a new drug called lerociclib combined with standard hormone therapy in 100 people with advanced HR+/HER2- breast cancer. The goal was to see if the combination is safe and effective. However, the trial was terminated early, so the full results are not av…
Matched conditions: HR+/HER2- METASTATIC BREAST CANCER
Phase 2 • Sponsor: EQRx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New pill shows promise against tough breast and ovarian cancers
Disease control Stopped earlyThis study tested an experimental drug (PF-06873600) taken by mouth, alone or with hormone therapy, in people with advanced breast or ovarian cancers. The goal was to check safety and see if the drug could shrink tumors. The trial was stopped early, but results help guide future …
Matched conditions: HR+/HER2- METASTATIC BREAST CANCER
Phase 1/2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC